Ageing: Postponing Morbidity
DOI:
https://doi.org/10.17140/EPOJ-3-112Keywords:
Ageing, Morbidity, Anabolic/Androgenic hormones, Growth hormone, ErythroprotetinAbstract
Aim
To investigate whether the morbidities associated with ageing – loss of muscle mass with consequent weakness, increase in adipose-tissue mass, thinning of skin, loss of bone mineral density followed by increase in fracture rate, decreased energy, and reduction in bone marrow output – can be prevented or postponed by a combination of modern pharmaceutical agents.
Methods
Electronic databases were scrutinized for the actions and side-effects of compounds which have known and specific effects.
Results
Anabolic steroids, androgenic hormones and their precursors, as well as growth hormone and erythropoietin were assessed. The benefits of each of these, and their potential adverse effects, together with suggested doses at which they may be used in combination, are presented.
Conclusions
The data indicate that there are many probable benefits to ageing individuals in postponing morbidity by the suggested combination of compounds, although no size effects can be determined without a large population study. It is likely that there would be a low-level of side-effects. However, before a population study, a clinical trial to test these assumptions is suggested. Apart from the specific benefit to individuals, if successful the combination would engender wide-spread usage with many important benefits to society, not least on the amount and cost of care-giving.
References
FriesJF.Aging,naturaldeath,andthecompressionof morbidity. N Engl J Med.1980;303:130-135.doi:10.1056/NEJM198007173030304
Hayflick L. Biological aging is no longer an unsolved problem. Ann N Y Acad Sci. 2007; 1100: 1-13. doi: 10.1196/annals.1395.001
Finch CE, Schneider EL. The future of old age. In: Brocklehurst’s Textbook of Geriatric Medicine and Gerontology. Eds. Fillit HM, Rock-wood K, Young J. 8th Ed. Amsterdam, Netherlands: Elsevier. 2017; 3: 10-15.
Buckley G. Martindale: The extra pharmacopoeia (29th edition). J R Coll Gen Pract. 1989; 1383-1384.
Gooren LJ, Bunck MC. Androgen replacement therapy: Present and future. Drugs. 2004; 64: 1861-1891.
Wilson JD. The role of 5α-reduction in steroid hormone physi-ology. Reprod Fertil Dev. 2001; 13: 673-678.
Nieschlag E. Testosterone treatment comes of age: New op-tions for hypo-gonadal men. Clin Endocrinol (Oxf). 2006; 65: 275- 281. doi: 10.1111/j.1365-2265.2006.02618.x
Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Soci-ety Clinical Practice Guideline. J Clin Endocrinol Metab. 2010; 95: 2536-2559. doi: 10.1210/jc.2009-2354
Cherrier MM, Matsumoto AM, Amor JK, et al. Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment. Neurology. 2005; 64: 2063-2068. doi:
1212/01.WNL.0000165995.98986.F1 10. Lu PH, Masterman DA, Mulnard R, et al. Effects of testoster-one on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. Arch Neurol. 2006; 63: 177-185. doi: 10.1001/archneur.63.2.nct50002
Malkin CJ, Pugh PJ, West JN, et al. Testosterone therapy in men with moderate severity heart failure: A double- blind randomised placebo controlled trial. Eur Heart J. 2006; 27: 57-64. doi: 10.1093/ eurheartj/ehi443
Caminiti G, Volterrani M, Iellamo F, et al. Effect of long-act-ing testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled randomized study. J Am Coll Cardiol. 2009; 54: 919-927. doi: 10.1016/j.jacc.2009.04.078
Vermeulen A. Dehydroepiandrosterone Sulfate and aging. Annals of NY Acad Sci. 1995; 774: 121-127. doi: 10.1111/j.1749- 6632.1995.tb17376.x Systematic Review | Volume 3 | Issue 1| Wiseman R
Morales AJ, Nolan JJ, Nelson JC, Yen SSC. Effects of Replace-ment dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab. 1994; 78: 1360-1367. doi: 10.1210/jcem.78.6.7515387
Casson PR, Andersen RN, Herrod HG, et al. Oral dehydro-epiandrosterone in physiologic dose modulated immune function in postmenopausal women. Am J Obstet Gynecol. 1993; 169: 1536- 1539.
Yen SSC, Morales AJ, Khorram O. Replacement of DHEA in aging men and women. Potential Remedial Effects. Ann NY Acad Sci. 1995; 774: 128-142.
Raynaud JP. Prostatic cancer risk in testosterone-treated men. J Steroid Biochem Mol Biol. 2006; 102: 261-266. doi: 10.1016/j.js-bmb.2006.09.032
Gould DC, Kirby RS. Testosterone replacement therapy for late onset hypogonadism: What is the risk of inducing prostatic cancer? Prostate Cancer Prostatic Dis. 2006: 9; 14-18. doi: 10.1038/ sj.pcan.4500839
Ishak KG, Zimmerman HJ. Hepatotoxic effects of theana-bolic/androgenic steroids. Semin Liver Dis. 1987; 7: 230-236. doi: 10.1055/s-2008-1040579
Søe KL, Søe M, Gluud C. Liver pathology associated with the use of the anabolic-androgenic steroids. Liver. 1992; 12: 73-79.
FDA. Drug Safety Communication. FDA evaluating risk of stroke, heart attack and death with FDA-approved testosterone products. Website: https://www.fda.gov/Drugs/DrugSafety/ ucm436259.htm. Accessed Jan 2014.
Araujo AB, Kupelian V, Page ST, et al. Sex steroids and all-cause and cause-specific mortality in men. Arch Intern Med. 2007; 167: 1252-1260. doi: 10.1001/archinte.167.12.1252
Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med. 2006; 166: 1660-1665. doi: 10.1001/archinte.166.15.1660
Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum tes-tosterone and mortality in older men. J Clin Endocrinol Metab. 2008; 63: 68-75. doi: 10.1210/jc.2007-1792
Tivesten A, Vandenput L, Labrie F, et al. Low serum testoster-one and estradiol predict mortality in elderly men. J Clin Endocrinol Metab. 2009; 94: 2482-2488. doi: 10.1210/jc.2008-2650
Barrett-Connor E, Goodman-Gruen D. The epidemiology of DHEAS and cardiovascular disease. Annals of NY Acad Sci. 1995; 774: 259-270.
Casson PR, Andersen RN, Faquin LC, et al. Replacement of dehydro- epiandrosterone enhances T-lymphocyte insulin binding in postmenopausal women. Fertil Steril. 1995; 63: 1027-1031.
Herbert J. The age of dehydroepiandrosterone. Lancet. 1995; 345: 1193-1194.
Weksler ME. Hormone replacement for men. Brit med J. 1996; 312: 859-860.
Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med. 1990; 323 (1): 1-6. doi: 10.1056/NEJM199007053230101
Sönksen P. Who needs growth hormone? J R Soc Med. 1995; 88: 179.
McGauley GA. Quality of life assessment before and after growth hormone treatment in adults with growth hormone defi-ciency. Acta Paediatr Scand Suppl. 1989; 356: 70-72.
Cuneo RC, Salomon F, McGauley GA, Sönksen P. The growth hormone deficiency syndrome in adults. Clinical Endocrinology. 1992; 37: 387-397.
Shalet SM, Holmes SJ. Growth hormone replacement in adults. BMJ. 1994; 308: 1314.
Cuneo RC, Salomon F, Wiles CM, et al. Histology of skeletal muscle in adults with GH deficiency: Comparison with normal muscle and response to GH treatment. Horm Res. 1992; 37: 23-28. Submit your article to this journal | https://openventio.org/submit-manuscript/ doi: 10.1159/000182276
Russell-Jones DL, Weissberger AJ, Bowes SB, et al. The effects of growth hormone on protein metabolism in adult growth hor-mone deficient patients. Clin Endocrinol (Oxf). 1993; 38: 427-431.
Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with re-combinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987; 316(2): 73-78. doi: 10.1056/ NEJM198701083160203
Winearls CG, Oliver DO, Pippard MJ, et al. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet. 1986; 2: 1175-1178.
Liu S, Ren J, Hong Z, et al. Efficacy of erythropoietin com-bined with enteral nutrition for the treatment of anemia in Crohn’s disease: A prospective cohort study. Nutr Clin Pract. 2013; 28 (1): 120-127. doi: 10.1177/0884533612462744
Martindale. The extra Pharmacopoeia. 39th edition 2017; Vol A: 1167-1171.
Momaya A, Fawal M, Estes R. Perfomance-enhancing sub-stances in sports: A review of the literature. Sports Med. 2015; 45 (4): 517-531. doi: 10.1007/s40279-015-0308-9
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Epidemiology (EOJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.